Abstract
Cefodizime (THR-221, CDZM), a new parenteral cephalosporin, was evaluated for its efficacy and safety in 20 children with bacterial infections (Table 1), and the following results were obtained.
1. CDZM was administered in 3 or 4 divided doses at daily dosages ranging from 54.5 to 84.2mg/kg administered by 30 minutes drip infusion or intravenous injection to 20 patients (7 cases of acute tonsillitis, 6 cases of pneumonia, 2 cases each of bronchitis and suppurative cervical lymphadenitis, and 1 case each of acute pharyngitis, acute enteritis and furunculosis) and the following clinical results were obtained: excellent, 7 cases; good, 11 cases; fair, 2 cases. The overall efficacy rate was 90% (Table 4).
2. MICs of CDZM against 15 strains of isolated organisms are shown in Table 2. MICs against all 7 strains of Haemophilus influenzae were less than 0.025μg/ml. MIC against 1 out of 5 strains of Streptococcus pneumoniae was 0.05μg/ml and those against 2 strains were 0.10μg/ml and against the other 2 were 0.20μg/ml. MICs against 3 strains of Staphylococcus aureus were 1.56, 25 and higher than 100μg/ml, respectively.
3. No clinical adverse reaction was observed in any of the 20 patients. Eosinophilia was observed in 2 cases. A slight elevation of S-GOT was found in 1 patient (case No.8) and moderate elevation of S-GOT and S-GPT in another (case No.18)(Table 4). In case No.18, the S-GOT and S-GPT activity improved after the administration of the drug was stopped.
4. These data suggest that CDZM is a useful new antibiotic in the treatment of children with susceptible bacterial infections and may be used as a first choice antibiotic for the treatment of respiratory tract infection in children.
